High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients

Table 2

The list of genes deriving from infiltrating immune or nonmalignant stromal cells (𝑛=10): The differences in gene expression between patient tumour sample and cell lines or between patient tumour sample and normal muscle tissue.

Gene name	Comparison	Log ratio	Fold change	𝑞-value	𝑃 value
SPP1	versus cell lines	5,608	48,757	1,22𝐸-17	2,62𝐸-20
	versus muscle	4,823	28,308	9,28𝐸-19	7.30𝐸-19
CXCR4	versus cell lines	3,870	14,621	2,00𝐸-04	7,55𝐸-05
	versus muscle	3,700	12,999	9,52𝐸-22	4,67𝐸-22
CD14	versus cell lines	3,089	8,509	8,47𝐸-15	4,10𝐸-17
	versus muscle	2,431	5,391	6,04𝐸-15	8,62𝐸-15
FOS	versus cell lines	2,984	7,911	5,19𝐸-05	1,44𝐸-05
	versus muscle	2,346	5,086	1,37𝐸-04	9,04𝐸-04
TNFAIP3	versus cell lines	2,065	4,186	3,65𝐸-05	9,29𝐸-06
	versus muscle	1,411	2,659	1,46𝐸-09	4,86𝐸-09
SOCS3	versus cell lines	1,940	3,837	1,30𝐸-08	6,82𝐸-10
	versus muscle	1,793	3,464	6,81𝐸-09	2,50𝐸-08
HSPA6	versus cell lines	1,584	2,998	1,03𝐸-07	7,79𝐸-09
	versus muscle	1,353	2,554	8,41𝐸-08	3,65𝐸-07
IL8	versus cell lines	1,368	2,582	1,55𝐸-03	9,18𝐸-04
	versus muscle	1,500	2,828	1,02𝐸-07	4,49𝐸-07
IL23A	versus cell lines	1,259	2,393	1,13𝐸-05	2,20𝐸-06
	versus muscle	1,336	2,525	9,77𝐸-14	1,70𝐸-13
STAT2	versus cell lines	1,259	2,393	1,13𝐸-05	2,20𝐸-06
	versus muscle	1,336	2,525	9,77𝐸-14	1,70𝐸-13